2011年10月7日，美国食品药品管理局(FDA)宣布批准Juvisync(西他列汀+辛伐他汀)用于治疗同时患有2型糖尿病和高脂血症的成人患者。Juvisync是一种固定剂量复方制剂，其所含的两种药物此前均已获准。只允许对同时具有这两种药物适应证的患者开具这种复方制剂的处方。 西他列汀是一种二肽基肽酶-4抑制剂，可增强人体自身的降糖能力，已被批准与饮食和运动疗法联合用于改善成人2型糖尿病患者的血糖控制水平。辛伐他汀是3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂或称他汀类药物的一种，已获准与饮食和运动疗法联合用于降低血液低密度脂蛋白胆固醇水平。 Juvisync已获准的剂量强度包括(西他列汀/辛伐他汀)100 mg/10 mg、100 mg/20 mg和100 mg/40 mg三种。生产商已开始研发含有50 mg西他列汀的药片，即Juvisync 50 mg/10 mg、50 mg/20 mg和50 mg/40 mg。在含有50 mg西他列汀的药片上市之前，需要使用该剂量药物的患者应服用单一成分的西他列汀药片。 Juvisync的最常见不良反应包括上呼吸道感染、鼻塞或流涕、咽痛、头痛、肌痛、腹痛、便秘和恶心。 制造商： 默克制药公司 类药物： 二肽基肽酶-4（DPP - 4）抑制剂+ HMG - CoA还原酶抑制剂。 活性成分（S）： 西他列汀，辛伐他汀; 100mg/10mg，100mg/20mg，100mg/40mg;选项卡。 指示（S）： 患者对他们来说，西他列汀和辛伐他汀治疗是适当的。西他列汀作为辅助饮食和运动改善血糖控制与2型糖尿病的成年人表示。辛伐他汀作为辅助治疗，在饮食上表示：，减少冠心病死亡，总死亡率降低风险和减少非致命性心肌梗塞，中风和冠脉事件的高风险患者的血管重建手术的需要的危险;降低升高的总减少血症患者载脂蛋白B，C，LDL - C的，TG和增加HDL - C的原发性高脂血症（杂合子家族性和nonfamilial）和混合血脂异常患者;升高TG和降低TG和VLDL - C dysbetalipoproteine​​mia患者;减少纯合子家族性高胆固醇血症患者的总- C和LDL - C水平。 药理： 西他列汀是一个DPP - 4抑制剂，这被认为是施加其行动与2型糖尿病患者肠促胰岛素激素的灭活减慢。西他列汀示范选择性的DPP - 4和浓度近似那些从治疗剂量不抑制DPP - 8或DPP - 9体外活性。辛伐他汀是一种HMG - CoA还原酶，酶催化的HMG - CoA转化为甲羟戊酸，早期和速率限制步骤中的胆固醇的生物合成途径的特异性抑制剂。另外，辛伐他汀可降低VLDL和TG和增加HDL - C的。 临床试验： 西他列汀和辛伐他汀的安全性和有效性进行了研究，在多个临床研究。 法律分类： 接收 成人： 燕子整体。给单剂量为每日的下午。最初100mg/40mg每天。已经在辛伐他汀的患者：每天开始西格列汀100毫克剂量辛伐他汀已经上当受骗。如果需要≥4个星期后调整剂量。同时服用维拉帕米，地尔硫卓：最大每一天100mg/10mg。同时服用胺碘酮，氨氯地平，雷诺嗪：每天最大100mg/20mg。纯合子家族性高胆固醇血症：每一天100mg/40mg。中国患者服用降脂修改剂量含烟酸产品（≥1g/day烟酸）：谨慎100mg/40mg剂量;肌病的风险增加。 儿童： <18yrs：不推荐。 禁忌（S）： 伴随强CYP3A4抑制剂（如酮康唑，伊曲康唑，泊沙康唑，红霉素，克拉霉素，泰利霉素，HIV蛋白酶抑制剂，奈法唑酮）。同时服用吉非贝齐，环孢素，达那唑。活动性肝病。怀孕（Cat.X）。哺乳的母亲。 警告/注意事项： 不适用于治疗1型糖尿病或糖尿病酮症酸中毒。中度至重度肾功能不全或终末期肾病：不推荐。开始治疗前评估肾功能并在此后定期。监测胰腺炎，肌酸激酶明显升高（> 10倍ULN的），肌病;停止，如果发生。暂时截留的剂量，如果发生急性或严重的条件下诱发肾功能衰竭，继发横纹肌溶解的发展。监测肝功能基线，然后根据需要。肝脏疾病的历史。大量的酒精消费。血管性水肿的历史与其他DPP - 4抑制剂。老人。 相互作用（S）： 见禁忌。同时磺脲类或胰岛素：这些减少剂量，以减少低血糖的风险。减少最大辛伐他汀剂量胺碘酮，维拉帕米，地尔硫，氨氯地平，雷诺嗪，伏立康唑，必须使用。注意与其他贝特类药物，秋水仙碱。避免大量葡萄柚汁（> 1夸脱每天）。监测地高辛，香豆素类抗凝血剂。 不良反应（S）： 上呼吸道感染，头痛，腹痛，便秘，恶心，鼻咽炎;胰腺炎，肌病，横纹肌溶解症，过敏反应（终止如果发生），糖化血红蛋白和空腹血糖水平增加。 如何提供： 标签- 30，90，1000 最后更新： 2011年11月3日 JUVISYNC Manufacturer: Merck & Co., Inc. Pharmacological Class: Dipeptidyl peptidase-4 (DPP-4) inhibitor + HMG-CoA reductase inhibitor. Active Ingredient(s): Sitagliptin, simvastatin; 100mg/10mg, 100mg/20mg, 100mg/40mg; tabs. Indication(s): In patients for whom treatment with both sitagliptin and simvastatin is appropriate. Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Simvastatin is indicated as an adjunctive therapy to diet to: reduce risk of total mortality by reducing CHD deaths and reduce risk of non-fatal MI, stroke, and the need for revascularization procedures in patients at high risk of coronary events; reduce elevated total-C, LDL-C, Apo B, TG and increase HDL-C in patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia; reduce elevated TG in patients with hypertriglyceridemia and reduce TG and VLDL-C in patients with primary dysbetalipoproteinemia; reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia. Pharmacology: Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones. Sitagliptin demonstrates selectivity for DPP-4 and does not inhibit DPP-8 or DPP-9 activity in vitro at concentrations approximating those from therapeutic doses. Simvastatin is a specific inhibitor of HMG-CoA reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol. In addition, simvastatin reduces VLDL and TG and increases HDL-C. Clinical Trials: The safety and efficacy of sitagliptin and simvastatin have been studied in multiple clinical studies. Legal Classification: Rx Adults: Swallow whole. Give as single daily dose in the PM. Initially 100mg/40mg per day. Patients already on simvastatin: start with sitagliptin 100mg daily and the dose of simvastatin already being taken. Adjust dose if needed after ≥4 weeks. Concomitant verapamil, diltiazem: max 100mg/10mg per day. Concomitant amiodarone, amlodipine, ranolazine: max 100mg/20mg per day. Homozygous familial hypercholesterolemia: 100mg/40mg per day. Chinese patients taking lipid-modifying doses (≥1g/day niacin) of niacin-containing products: caution with 100mg/40mg dose; increased risk of myopathy. Children: <18yrs: not recommended. Contraindication(s): Concomitant strong CYP3A4 inhibitors (eg, itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone). Concomitant gemfibrozil, cyclosporine, danazol. Active liver disease. Pregnancy (Cat.X). Nursing mothers. Warnings/Precautions: Not for treating type 1 diabetes or diabetic ketoacidosis. Moderate-to-severe renal impairment or ESRD: not recommended. Assess renal function prior to starting therapy and periodically thereafter. Monitor for pancreatitis, markedly elevated creatine kinase (>10x ULN), myopathy; discontinue if occurs. Temporarily withhold dose if experiencing acute or serious condition predisposing to development of renal failure secondary to rhabdomyolysis. Monitor liver function at baseline, then as needed. History of liver disease. Substantial alcohol consumption. History of angioedema with other DPP-4 inhibitors. Elderly. Interaction(s): See Contraindications. Concomitant sulfonylurea or insulin: reduce dose of these to reduce risk of hypoglycemia. Reduce max simvastatin dose if amiodarone, verapamil, diltiazem, amlodipine, ranolazine, voriconazole must be used. Caution with other fibrates, colchicine. Avoid large quantities of grapefruit juice (>1 quart daily). Monitor digoxin, coumarin anticoagulants. Adverse Reaction(s): Upper respiratory infection, headache, abdominal pain, constipation, nausea, nasopharyngitis; pancreatitis, myopathy, rhabdomyolysis, hypersensitivity reactions (discontinue if occurs), increased A1C and fasting serum glucose levels. How Supplied: Tabs—30, 90, 1000 Last Updated: 11/3/2011